The data are now overwhelming that the most cost-efficient primary screen for women over the age of 30–35 should be a test for high-risk types of human papillomavirus. A self-collected sample expands coverage by overcoming many of the known obstacles to participation in a screening programme. In addition, self-sampling has the potential to be the most effective means to achieve high coverage rates in medically underserved regions of the world that lack the healthcare infrastructure to support traditional screening programmes. Self-collection combined with high throughput, low cost-per-case, polymerase chain reaction-based technology has the sensitivity of a direct endocervical sample obtained by a physician. Therefore, we have the technology to reach millions of women around the world in a short period of time through large ‘event-type’ screening programmes and centralised testing. Now we need to focus on developing the models that will enable us to efficiently place the technologies next to the women who need them the most.
Share this Article
Related Content In Gynaecological Oncology
Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors
European Oncology & Haematology. 2019;15(1):29–40 DOI: https://doi.org/10.17925/EOH.2019.15.1.29
Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living within 5 years of an ovarian cancer diagnosis.1 In the EU, age-adjusted ovarian […]
Advances in the Treatment of Endometrial and Ovarian Cancer
Oncology & Hematology Review. 2019;15(1):23–4 DOI: https://doi.org/10.17925/OHR.2019.15.1.23
Gynecological malignancies can be difficult to treat. Ovarian cancer carries with it the worst prognosis of all gynecological cancers. Approximately 75% of patients with epithelial ovarian cancer are diagnosed with advanced disease which is curable only in a minority of cases, resulting in a 5-year overall survival rate of only 20–30%. However, survival at all […]
The Belarus Experience of Pelvic Artery Embolisation in Patients with Advanced and Recurrent Cervical Cancer Presenting with Haemorrhage
European Oncology & Haematology, 2018;14(1):45–49 DOI: https://doi.org/10.17925/EOH.2018.14.1.45
Cervical cancer (CC) is a leading cause of cancer morbidity in women globally. In Europe, epidemiological data on CC incidence shows important differences between countries: from 3.6 per 100,000 women in Switzerland to 28.6 per 100,000 in Romania.1,2 In 2015 in the Republic of Belarus, the morbidity and mortality rate from CC were 11.9 and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!